Spots Global Cancer Trial Database for A Study to Investigate FP002 in Subjects With Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Investigate FP002 in Subjects With Advanced Malignancies
Official Title: A Phase 1 Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP002 in Subjects With Advanced Malignancies
Study ID: NCT05982080
Conditions
Interventions
Study Description
Brief Summary: The goal of this phase 1 study is to assess the safety, and tolerability of FP002 to determine the dose recommended for dose expansion in subjects with advanced solid tumor.
Detailed Description: This study is a phase 1 study of FP002 as monotherapy in patients with advanced solid tumor. The study will evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile, immunogenicity, and preliminary anti-tumor activity of FP002 in patients with advanced solid tumors.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Shangdong Cancer Hospital & Institute, Jinan, Shangdong, China
Linyi Cancer Hospital, Linyi, Shangdong, China
Contact Details
Name: Yuping Sun, MD
Affiliation: Shangdong Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Linlin Wang, MD
Affiliation: Shangdong Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
